Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA1 | Q09470 | 1/20 | 0.41 |
| ▸ | KCNAB1 | Q14722 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | HPGD | P15428 | 5/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9922367 | 0.96 | ALDH1A1 (0.45) | KCNA1KCNAB1ALDH1A1MAPTLMNA | |
| SCHEMBL9922960 | 0.90 | KMT2A (0.40) | KCNA1KCNAB1ALDH1A1MAPTLMNA | |
| SCHEMBL14228354 | 0.90 | KMT2A (0.39) | ALDH1A1MAPTLMNAKDM4EKMT2A | |
| SCHEMBL9922959 | 0.89 | PTGER3 (0.41) | KCNA1KCNAB1ALDH1A1MAPTLMNA | |
| SCHEMBL9922950 | 0.88 | KMT2A (0.43) | ALDH1A1MAPTLMNAKMT2AHPGD | |
| SCHEMBL9922184 | 0.88 | MEN1 (0.40) | ALDH1A1MAPTLMNAKMT2AHPGD | |
| SCHEMBL9922186 | 0.88 | KMT2A (0.39) | ALDH1A1MAPTLMNAKMT2AHPGD | |
| SCHEMBL9922372 | 0.88 | MEN1 (0.40) | ALDH1A1MAPTLMNAKMT2AHPGD | |
| SCHEMBL13638607 | 0.87 | MEN1 (0.42) | KCNA1KCNAB1ALDH1A1MAPTLMNA | |
| SCHEMBL9922383 | 0.87 | KMT2A (0.41) | ALDH1A1MAPTLMNASMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524721-B2 | Platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-8067428-B2 | Platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067428-B2 | Platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20100234350-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100234350-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-7622474-B2 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622474-B2 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7358257-B2 | sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, antithrombotic agents | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358257-B2 | sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, antithrombotic agents | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234350-A1 | PLATELET ADP RECEPTOR INHIBITORS | TBXA2R, GP6, P2RY6 | KCNA1 1233/4885KCNAB1 2237/4885ALDH1A1 1369/4885 |
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | TBXA2R, GP6, P2RY6 | KCNA1 1257/4885KCNAB1 2262/4885ALDH1A1 1379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.